ReviewCurrent molecular medicine2025
The Emerging Role of Long Non-coding RNA 01296 in Human Malignancies.
Review in Current molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of long non-coding RNA HCG11 in human cancers: From molecular mechanisms to clinical applications (Review).Oncology letters · 2026Review
- VPS9D1-AS1: a critical oncogenic long non-coding RNA in human malignancies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- LncRNA NKILA as a key regulator in cancer pathogenesis: insights into its mechanisms and clinical implications.Cancer cell international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) refer to a group of RNA molecules that exceed a length of 200 nucleotides and lack the ability to code proteins. Numerous studies suggest that lncRNAs significantly contribute to the onset and progression of various forms of cancers. A specific lncRNA, known as long non-coding RNA 01296 (LINC01296), is extensively expressed in human malignancies. The level of LINC01296 has been shown to correlate with the progression and prognosis of cancers. Moreover, numerous scientific investigations have provided evidence that the dysregulation of LINC01296 functioning as a competitive endogenous RNA (ceRNA) exerts a profound influence on various aspects of cancer cell behavior, including proliferation, apoptosis, invasion, metastasis, and cell cycle progression, by means of regulating target genes and signaling pathways. An increasing body of data strongly suggests that LINC01296 may serve as a valuable biomarker for predicting cancer prognosis and could represent a promising therapeutic target for cancer intervention. In this comprehensive review, we summarize the recent advancements in our understanding of the role, underlying mechanisms, and clinical significance of LINC01296 in malignant tumors. The findings suggest that LINC01296 may be both a reliable biomarker and a potential therapeutic target for cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.